Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
Novartis
Johnson and Johnson
McKinsey
Chinese Patent Office
Medtronic
Federal Trade Commission
Mallinckrodt
McKesson
QuintilesIMS

Generated: December 12, 2017

DrugPatentWatch Database Preview

WELLBUTRIN Drug Profile

« Back to Dashboard

When do Wellbutrin patents expire, and what generic alternatives are available?

Wellbutrin is a drug marketed by Glaxosmithkline and Valeant Intl and is included in three NDAs. There is one patent protecting this drug and one Paragraph IV challenge.

The generic ingredient in WELLBUTRIN is bupropion hydrochloride. There are thirty-seven drug master file entries for this compound. Seventy-five suppliers are listed for this compound. Additional details are available on the bupropion hydrochloride profile page.

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
GlaxosmithklineWELLBUTRINbupropion hydrochlorideTABLET;ORAL018644-001Dec 30, 1985DISCNYesNo► Subscribe► Subscribe► Subscribe► Subscribe
GlaxosmithklineWELLBUTRIN SRbupropion hydrochlorideTABLET, EXTENDED RELEASE;ORAL020358-004Jun 14, 2002AB1RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
GlaxosmithklineWELLBUTRIN SRbupropion hydrochlorideTABLET, EXTENDED RELEASE;ORAL020358-001Oct 4, 1996DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Valeant IntlWELLBUTRIN XLbupropion hydrochlorideTABLET, EXTENDED RELEASE;ORAL021515-001Aug 28, 2003AB3RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
GlaxosmithklineWELLBUTRINbupropion hydrochlorideTABLET;ORAL018644-002Dec 30, 1985DISCNYesNo► Subscribe► Subscribe► Subscribe► Subscribe
GlaxosmithklineWELLBUTRINbupropion hydrochlorideTABLET;ORAL018644-003Dec 30, 1985DISCNYesNo► Subscribe► Subscribe► Subscribe► Subscribe
GlaxosmithklineWELLBUTRIN SRbupropion hydrochlorideTABLET, EXTENDED RELEASE;ORAL020358-003Oct 4, 1996AB1RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
GlaxosmithklineWELLBUTRIN SRbupropion hydrochlorideTABLET, EXTENDED RELEASE;ORAL020358-002Oct 4, 1996AB1RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Valeant IntlWELLBUTRIN XLbupropion hydrochlorideTABLET, EXTENDED RELEASE;ORAL021515-002Aug 28, 2003AB3RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for WELLBUTRIN

Drugname Dosage Strength RLD Submissiondate
bupropion hydrochlorideExtended-release Tablets150 mg and 300 mgWellbutrin XL9/21/2004

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Express Scripts
Cipla
Johnson and Johnson
UBS
Queensland Health
Daiichi Sankyo
Citi
Cantor Fitzgerald
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot